Fractyl Health will use the IPO proceeds for pivotal testing of a medical device and surgical procedure intended to address root causes of diabetes and obesity. The Fractyl pipeline also includes a gene therapy for these conditions.
Metabolic Disorder-Focused Fractyl Health ‘GUTS’ Out a $110 Million IPO
